GleamWall
中文EN

PDSB PDS Biotechnology Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1472091 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7.5%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-281.4%
ROA-121.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets27.3%
Debt / equity0.00x
Current ratio3.62x
Interest coverage-3.52x

Cash quality & payout

Operating cash flow / net income0.59x
Accruals ratio-49.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q42025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue————————
R&D expense$2.05M$3.27M$3.46M$4.41M$4.58M$4.21M$5.83M$4.53M
SG&A expense$3.84M$3.23M$3.06M$2.27M$3.56M$3.41M$3.27M$2.83M
Operating income-$5.90M-$6.50M-$6.52M-$6.67M-$8.14M-$7.62M-$9.11M-$7.36M
Interest expense$1.77M$3.38M$1.01M$1.11M$1.15M$2.14M$930,878$1.10M
Pretax income-$7.62M-$9.75M-$7.35M-$7.56M-$9.01M-$9.43M-$9.66M-$7.95M
Income tax$0$0$0$0$0$0-$1.17M$0
Net income-$7.62M-$9.75M-$7.35M-$7.56M-$9.01M-$9.43M-$8.49M-$7.95M
EBITDA-$5.89M-$6.49M-$6.52M-$6.67M-$8.13M-$7.62M-$9.10M-$7.36M
EPS (basic)-0.11-0.18-0.13—-0.19-0.21-0.21—
EPS (diluted)-0.11-0.18-0.13—-0.19-0.21-0.21—
Weighted avg. shares (diluted)71.94M55.66M55.50M—46.87M45.90M40.52M—
Balance sheet
Cash & equivalents$15.25M$5.60M$21.66M$26.71M$26.20M$31.87M$39.98M$41.69M
Current assets$18.37M$7.05M$22.89M$28.25M$27.89M$33.65M$42.47M$45.05M
PP&E, net$168,225$176,612$114,725$120,184$125,643$131,102$136,561$142,020
Total assets$18.57M$8.81M$24.66M$30.49M$34.71M$40.48M$47.03M$45.36M
Current liabilities$5.08M$12.38M$10.15M$9.48M$13.33M$11.53M$18.27M$17.09M
Total liabilities$5.08M$12.39M$20.77M$21.24M$25.25M$24.52M$24.67M$26.35M
Shareholders' equity$13.50M-$3.58M$3.89M$9.25M$9.45M$15.96M$22.36M$19.00M
Shares outstanding104.21M55.92M55.82M54.88M47.71M46.63M45.45M37.99M
Cash flow statement
Operating cash flow-$8.22M-$2.79M-$4.37M-$3.70M-$5.92M-$9.10M-$9.03M-$8.23M
Capital expenditure———$0$0——$0
Free cash flow———-$3.70M-$5.92M——-$8.23M
Investing cash flow———$0$0——$0
Financing cash flow$17.87M-$13.27M-$679,827$4.22M$241,205$995,944$7.32M$172,778
Depreciation & amortization$8,387$8,387$5,459$5,459$5,459$5,459$5,459$5,458
Stock-based compensation$840,221$1.13M$1.16M$1.16M$1.25M$448,029$1.25M$1.64M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.